Resource type
Date created
2008-12
Authors/Contributors
Author: Lee, Nancy
Author: Lestou, Valia S.
Abstract
viDA Therapeutics Inc. (herein called viDA), with headquarters in Vancouver, British Columbia, was incorporated in April of 2008. viDA is a new specialty biotechnology company focused on the discovery, development and commercialization of first-in-class drugs for the treatment of age-related degenerative processes, such as age related wrinkling and hair loss. viDA has chosen a distinct company strategy, focusing strongly on the development and marketing of specialty products. viDA bases its business model in the remarkable and patented discoveries surrounding granzymes. Granzymes have been shown to play a central and pivotal role in the destruction of proteins vital in one’s body anti-aging processes that prevent skin wrinkling and hair loss. viDA is currently looking to secure an initial round of funding of $1.5 million for 2008 and an additional $6 million for 2009 to perform further target identification, target validation, preclinical research and early-stage clinical development. We recommend that viDA seeks the full $7.5 million in Series A an Series B financing simultaneously to ensure adequate funds to meet projected milestones.
Document
Description
MOT MBA Project-Simon Fraser University
Copyright statement
Copyright is held by the author(s).
Scholarly level
Peer reviewed?
No
Language
English
Member of collection
Download file | Size |
---|---|
input_data\nid_13154\MOT%20MBA%202008%20Nancy%20Lee%20%2526%20Valia%20Lestou.pdf | 2.55 MB |